440 related articles for article (PubMed ID: 26669603)
21. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer.
Zhou Y; Shen JK; Hornicek FJ; Kan Q; Duan Z
Oncotarget; 2016 Jun; 7(26):40846-40859. PubMed ID: 27049727
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in CDK inhibitors for cancer therapy.
Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
24. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker SR; Mallinger A; Workman P; Clarke PA
Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
[TBL] [Abstract][Full Text] [Related]
26. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
27. Cyclins and related kinases in cancer cells.
Malumbres M
J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
[TBL] [Abstract][Full Text] [Related]
28. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
[TBL] [Abstract][Full Text] [Related]
29. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
[TBL] [Abstract][Full Text] [Related]
30. Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.
Zhang J; Su G; Lin Y; Meng W; Lai JKL; Qiao L; Li X; Xie X
Discov Med; 2019 Jan; 27(146):27-36. PubMed ID: 30721649
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinase inhibitors: novel anticancer agents.
Mani S; Wang C; Wu K; Francis R; Pestell R
Expert Opin Investig Drugs; 2000 Aug; 9(8):1849-70. PubMed ID: 11060782
[TBL] [Abstract][Full Text] [Related]
33. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide.
Panigone S; Debernardi S; Taya Y; Fontanella E; Airoldi R; Delia D
Oncogene; 2000 Aug; 19(35):4035-41. PubMed ID: 10962560
[TBL] [Abstract][Full Text] [Related]
34. Selectivity and potency of cyclin-dependent kinase inhibitors.
Sridhar J; Akula N; Pattabiraman N
AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
[TBL] [Abstract][Full Text] [Related]
35. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
Choi SH; Kim S; Jones KA
Exp Mol Med; 2020 May; 52(5):762-771. PubMed ID: 32451425
[TBL] [Abstract][Full Text] [Related]
36. Preclinical and clinical development of palbociclib and future perspectives.
de Dueñas EM; Gavila-Gregori J; Olmos-Antón S; Santaballa-Bertrán A; Lluch-Hernández A; Espinal-Domínguez EJ; Rivero-Silva M; Llombart-Cussac A
Clin Transl Oncol; 2018 Sep; 20(9):1136-1144. PubMed ID: 29564714
[TBL] [Abstract][Full Text] [Related]
37. Cell Cycle Regulation in Treatment of Breast Cancer.
Cai Z; Liu Q
Adv Exp Med Biol; 2017; 1026():251-270. PubMed ID: 29282688
[TBL] [Abstract][Full Text] [Related]
38. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
Pitts TM; Davis SL; Eckhardt SG; Bradshaw-Pierce EL
Pharmacol Ther; 2014 May; 142(2):258-69. PubMed ID: 24362082
[TBL] [Abstract][Full Text] [Related]
39. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma.
Ramakrishnan VG; Kumar SK
Cancer J; 2016; 22(1):7-11. PubMed ID: 26841010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]